Loading clinical trials...

Effects of Online App Weight Loss Programs on Liver Health in Obese Adults | Clinical Trials | Clareo Health

COMPLETEDNA

Effects of Online App Weight Loss Programs on Liver Health in Obese Adults

A Single Arm Study to Assess the Effects of Online App Weight Loss Programs on Liver Health in Obese Adults

NCT05015491•Noom Inc.

Summary

The primary objective of this trial is to assess the effects of online app weight loss programs on liver health in obese adults.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Male or female, \>18 years of age, inclusive, at Day -7.
•BMI of 30.00 to 49.99 kg/m2, inclusive, at Day -7.
•Has no plan to change smoking habits during the study period.
•Has ability to access study related online programs and apps.
•Willing to follow study instructions, as well as complete online questionnaires.
•Understands the study procedures and signs forms providing informed consent to participate in the study and authorization for release of relevant protected health information to the study investigators, Sponsor and Collaborator.

Exclusion Criteria

•Self-reported presence of uncontrolled cardiac, renal, endocrine, pulmonary, biliary, pancreatic, gastrointestinal, or neurological disorders or cancer (except for non-melanoma skin cancer) that may affect the subject's ability to adhere to the study protocol and/or affect study outcomes as assessed by the PI.
•Self-reported type 1 diabetes.
•History of gastrointestinal surgery for weight reducing purposes.
•Participation in a weight loss trial or a program/service intended to alter body weight (e.g., Noom, Weight Watchers); medications, dietary supplements or products that affect weight loss, nutrient absorption, appetite and satiety; or weight loss or gain ≥10 lb (4.5 kg) within 6 mo of Day -7.
•Extreme dietary habits (e.g., Atkins diet, very high protein, intermittent fasting) or eating disorder.
•Female who is pregnant, planning to be pregnant during the study period, lactating, or is of childbearing potential and is unwilling to commit to the use of a medically approved form of contraception throughout the study period. The method of contraception must be recorded.
•Female with prior medical diagnosis of premenstrual syndrome or premenstrual dysphoric disorder.
•Unstable use of hormonal contraceptives, anti-hypertensive medication, medications for mental or emotional disorders, or thyroid hormones within 90 d of Day -7.
•Exposure to any non-registered drug product within 30 d of Day -7.
•Recent history of (within 12 mo of Day -7) or strong potential for alcohol or substance abuse. Alcohol abuse defined as \>14 drinks per week (1 drink = 12 oz beer, 5 oz wine, or
+2 more criteria

Locations (1)

Arizona Liver Health

Chandler, Arizona, United States

Key Dates

Start Date

August 9, 2021

Primary Completion Date

September 12, 2022

Completion Date

September 12, 2022

Last Updated

November 13, 2023

Enrollment

ACTUAL participants

Conditions

NASHFatty LiverNAFLDWeight Loss

Interventions

Noom Healthy Weight Program

BEHAVIORAL

A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)

NCT02815891

Nonalcoholic Fatty LiverNonalcoholic Steatohepatitis

View study

RECRUITINGNA

iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) vs Optimized Lifestyle Intervention for Weight Loss

NCT07237750

Overweight and/or ObesityMetabolic Syndrome+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 13, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Effects of Online App Weight Loss Programs on Liver Health in Obese Adults

Inclusion Criteria

Exclusion Criteria

A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)

iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) vs Optimized Lifestyle Intervention for Weight Loss

A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

Identification of Liver Fibrosis Biomarkers

Study of the Efficacy and Safety of Nicotinamide in Patients With Liver Fibrosis (NICOFIB)

A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH